Showing 3681-3690 of 4164 results for "".
- Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Thyroid Eye Disease (TED)https://modernod.com/news/viridian-announces-positive-data-from-ongoing-phase-12-trial-evaluating-vrdn-001-in-patients-with-thyroid-eye-disease-ted/2481240/Viridian Therapeutics announced positive topline clinical data from the first two cohorts in its ongoing phase 1/2 clinical trial of VRDN-001, an anti-IGF-1R antibody, in patients with active thyroid eye disease (TED). TED is a rare autoimmune disease in which the body’s own immune sys
- Claes H. Dohlman, MD, Cornea Research Pioneer and Visionary, Passes Away at 101https://modernod.com/news/claes-h-dohlman-md-cornea-research-pioneer-and-visionary-passes-away-at-101/2482356/Cornea Research Pioneer Claes H. Dohlman, MD, PhD, professor of Ophthalmology, Emeritus, and former Chief and Chair of the Department of Ophthalmology at Mass Eye and Ear and Harvard Medical School (HMS), passed away at the age of 101 on July 14, 2024, Mass Eye and Ear announced on Monday.
- American Academy of Optometry Announces 2026 Retina Summit in Indianapolishttps://modernod.com/news/american-academy-of-optometry-announces-2026-retina-summit-in-indianapolis/2486018/The American Academy of Optometry has announced the 2026 Retina Summit, a 1-day continuing education program focused on advancing clinical knowledge and patient care in retinal disease. The event will take place Saturday, April 18, 2026, at the Indianapolis Marriott
- FDA Officially Shifts to One-Trial Standard for New Drug Approvalshttps://modernod.com/news/fda-officially-shifts-to-one-trial-standard-for-new-drug-approvals/2485753/The FDA has announced a major change to its regulatory framework, formally establishing that a single well-designed pivotal clinical trial will be the new default basis for most drug and therapeutic approvals—replacing the long-standing expectation that two indepen
- Bausch + Lomb's Surgical Planning Software, Eyetelligence, Now Fully Commercially Available in UShttps://modernod.com/news/bausch-lombs-surgical-planning-software-eyetelligence-now-fully-commercially-available-in-us/2484204/Bausch + Lomb announced that its surgical planning software, Eyetelligence, is now available to all US ophthalmologists. Eyetelligence is designed to streamline a clinic’s operations and bring connectivity into the OR. According to B+L, the software helps surgeons make quick
- Aurion Announces Positive 12-Month Results from Phase 1/2 CLARA Trial of AURN001 Corneal Endothelial Cell Therapyhttps://modernod.com/news/aurion-announces-positive-12-month-results-from-phase-12-clara-trial-of-aurn001-corneal-endothelial-cell-therapy/2484196/Aurion Biotech announced positive 12-month results from its phase 1/2 CLARA clinical trial. The study evaluated the safety, efficacy, and tolerability of AURN001 (neltependocel [human corneal endothelial cells] in combination with Y-27632 rho-kinase inhibitor)
- Avisi Technologies Receives FDA Approval to Study Novel Approach to Glaucoma Treatmenthttps://modernod.com/news/avisi-technologies-receives-fda-approval-to-study-novel-approach-to-glaucoma-treatment/2484182/Avisi Technologies announced that the FDA has approved an investigational device exemption (IDE) for its glaucoma treatment device, VisiPlate. This milestone paves the way for the company’s SAPPHIRE clinical trial, which will evaluate the device in patie
- SpyGlass Pharma Announces Promising 24-Month Interim Results from First-in-Human Trial of BIM-IOL Systemhttps://modernod.com/news/spyglass-pharma-announces-promising-24-month-interim-results-from-first-in-human-trial-of-bim-iol-system/2484179/SpyGlass Pharma announced interim 24-month data from its first-in-human clinical trial evaluating the Bimatoprost Drug Pad-IOL System (BIM-IOL System). This technology integrates proprietary non-bioerodible drug pads with SpyGlass Pharma’s IOL, designed
- FDA Clears Complement Therapeutics’ IND Application for CTx001 Gene Therapy in GAhttps://modernod.com/news/fda-clears-complement-therapeutics-ind-application-for-ctx001-gene-therapy-in-ga/2484178/Complement Therapeutics has announced that the FDA has cleared its investigational new drug (IND) application for CTx001, the company’s lead gene therapy candidate. The clearance paves the way for the initiation of Opti-GAIN, a phase 1/2 clinic
- BVI Receives FDA Approval for Finevision HP Trifocal IOLhttps://modernod.com/news/bvi-receives-fda-approval-for-finevision-hp-trifocal-iol/2484174/BVI announced that the FDA has approved its Finevision HP trifocal IOL. According to BVI, Finevision HP was the world’s first trifocal IOL, with more than 15 years of clinical success a